Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.

PURPOSE Patients with metastatic castration-resistant prostate cancer (mCRPC) and advanced breast cancer (aBC) have poor outcomes with standard treatments. We report phase 1 results from the STESIDES (NCT03878823) study of ODM-209, an oral selective CYP11A1 inhibitor that blocks all synthesis of steroid hormones. MET...

A. Bernard-Tessier, I. Spanggaard, T. Utriainen et al. · 0 citations
Review Open access Sep 2026

PSMA-targeted radioligand therapy with beta emitters in prostate cancer: current evidence, emerging indications, combination strategies, and future directions

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has emerged as a major therapeutic advance in metastatic castration-resistant prostate cancer (mCRPC), The phase III VISION trial demonstrated that [ 177 Lu]Lu-PSMA-617 significantly improves overall survival and radiographic progression-f...

Hiba Noamen, Adam Bekkhoucha, A. Bernard-Tessier et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.